
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patien


















